Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement

2024/12/16

On December 12, 2024, Beilu Pharmaceutical participated in the bidding process for the 10th National Drug Centralized Procurement organized by the National Joint Drug Procurement Office. Beilu Pharmaceutical's Gadoterate Meglumine Injection is awarded the bid.

References

Related News

Beilu Pharma Established a Wholly-owned R&D Subsidiary
September 7, 2022Taking the "Top 100 Chinese Pharmaceutical Enterprises" as the medium and long-term goal, Beilu Pharma has decided to choose not only the Contrast Agent field, Central Nervous System (Propri...view
Frequently Asked Questions about Iodine Contrast Users (2)
May 13, 20211. Does the allergy test of iodinated contrast agents need to be done?The allergy test of iodinated contrast agents cannot reduce the risk of adverse reactions.view
Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API
August 15, 2025Recently, Hichi Pharmaceutical's Iomeprol API has received the "Approval Notice for the Market Application of Chemical APIs" from the NMPA. This is another blockbuster product approved f...view
Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical's Iopamidol Approved for Market Release
April 2, 2025Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is an...view
Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!
February 18, 2022Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...view
Beilu Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Indian Registration Certificate
July 25, 2025Recently, Zhejiang Hichi Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the Iodixanol API product registration certificate issued by the Central Drugs Stand...view

Beilu Pharmaceutical's Gadoterate Meglumine Injection Win the Bid for the 10th National Drug Centralized Procurement

Beilu Pharma Established a Wholly-owned R&D Subsidiary

Frequently Asked Questions about Iodine Contrast Users (2)

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API

Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical's Iopamidol Approved for Market Release

Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!

Beilu Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Indian Registration Certificate